Fairmount Funds Management LLC Insmed Inc Transaction History

Fairmount Funds Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 09, 2022	BUY	$20.88 - $28.21 $208,800 - $282,100	10,000 Added 0.75%	1,336,368 $28.8 Million
Q2 2022 Aug 15, 2022	SELL	$17.07 - $25.71 $10.6 Million - $16 Million	-622,416 Reduced 31.94%	1,326,368 $26.2 Million
Q1 2022 May 16, 2022	BUY	$20.42 - $28.13 $13 Million - $17.9 Million	635,177 Added 48.35%	1,948,784 $45.8 Million
Q3 2021 Nov 15, 2021	BUY	$22.46 - $29.47 $667,511 - $875,848	29,720 Added 2.31%	1,313,607 $36.2 Million
Q2 2021 Aug 13, 2021	BUY	$24.17 - $36.01 $7.78 Million - $11.6 Million	322,090 Added 33.49%	1,283,887 $36.5 Million
Q4 2020 Feb 12, 2021	SELL	$31.45 - $40.54 $2.99 Million - $3.85 Million	-95,000 Reduced 8.99%	961,797 $32 Million
Q3 2020 Nov 12, 2020	BUY	$26.0 - $34.5 $1.2 Million - $1.59 Million	46,000 Added 4.55%	1,056,797 $34 Million
Q2 2020 Aug 04, 2020	SELL	$14.11 - $29.42 $141,100 - $294,200	-10,000 Reduced 0.98%	1,010,797 $27.8 Million
Q1 2020 May 08, 2020	BUY	$13.63 - $33.98 $433,406 - $1.08 Million	31,798 Added 3.22%	1,020,797 $16.4 Million
Q4 2019 Feb 12, 2020	BUY	$16.12 - $24.98 $15.9 Million - $24.7 Million	988,999 New	988,999 $23.6 Million

484

182M

2.14M

3.25M

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $10.6B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

Get notified when there are updates to the investment portfolio of Fairmount Funds Management LLC, based on Form 13F filings with the SEC.

Stay updated on Fairmount Funds Management LLC with notifications on news.